Tuesday | Wednesday | Thursday | Friday | Saturday
THURSDAY, DECEMBER 6, 2018
     
6:45 am - 5:15 pm Registration - Main Lobby  
     
7:00 am - 9:00 am Spotlight Session 3: Next Steps in HER2+ Targeted Therapy - Stars at Night Ballroom 1&2 - 3rd Level
Chair: Ian Krop, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Discussants                         

Natural history and novel combinations for HER2+ disease
Sara Hurvitz, MD
University of California Los Angeles
Santa Monica, CA

Predictive and prognostic markers for HER2+ disease
Aleix Prat, MD, PhD
Hospital Clinic of Barcelona
Barcelona, SPAIN
 
     
7:00 am - 9:00 am Spotlight Session 4: Breast Cancer Screening and Imaging - Stars at Night Ballroom 3&4 - 3rd Level
Chair: David Mankoff, MD, PhD
University of Pennsylvania
Philadelphia, PA

Discussants:

Screening, diagnosis & residual disease detection
Janie M. Lee, MD, MSc
Seattle Cancer Care Alliance
Seattle, WA

Molecular imaging biomarkers
Farrokh Dehdashti, MD
Washington University School of Medicine
St. Louis, MO
 
     
7:00 am - 9:00 am

POSTER SESSION 2 & continental breakfast - Hall 1

 
 

Tumor Cell and Molecular Biology

 
 

Tumor Progression, Invasion and Metastasis
Metabolism and Breast Cancer
Signaling Pathways
Virology
Other
Novel/Emerging Therapeutics Targets

P2-01
P2-02
P2-03
P2-04
P2-05
P2-06

  Prognostic and Predictive Factors  
 

Prognostic Factor Index Scores
Other

P2-07
P2-08

  Treatment  
  Immunotherapy (Clinical)
Antiangiogenic Therapy (Adjuvant and Metastatic)
Antibody Based Regimens
Signal Transduction Inhibitors
Adjuvant Therapy
Surgery
Clinical Trial Design and Management
Patient Resources
P2-09
P2-10
P2-11
P2-12
P2-13
P2-14
P2-15
P2-16
     
9:00 am - 9:30 am PLENARY LECTURE 2 – Hall 3  
 

Neoadjuvant Endocrine Therapy: The Times They are A-Changing
Ingrid A. Mayer, MD, MSCI
Vanderbilt University Medical Center
Nashville, TN

 
     
9:30 am - 11:30 am

GENERAL SESSION 3 – Hall 3
Moderator: Angelo Di Leo, MD, PhD
Istituto Toscani Tumori
Prato, ITALY

 
     
9:30 am

GS3-01. A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

 
                           DeCensi A, Puntoni M, Guerrieri Gonzaga A, Avino F, Cortesi L, Donadio M, Pacquola M, Falcini F, Gulisano M, Digennaro M, Tienghi A, Cagossi K, Pinotti G, Varicchio C, Caviglia S, Boni L, Bonanni B.  E.O. Ospedali Galliera, Genoa, Italy; European Institute of Oncology, Milan, Italy; Istituto Nazionale Tumori "Fondazione Pascale, Naples, Italy; A. O. Universitaria Policlinico di Modena, Modena, Italy; A.O. Universitaria S. Giovanni Battista - “Le Molinette”, Turin, Italy; Ospedale SS Antonio e Margherita-ASL AL, Tortona, Italy; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy; ULSS 6 Vicenza, Vicenza, Italy; Ospedale Oncologico di Bari - Istituto Tumori “G. Paolo II”, Bari, Italy; Ospedale Santa Maria delle Croci, Ravenna, Italy; Ospedale Bernardino Ramazzini, Carpi (MO), Italy; Asst Sette Laghi, Varese, Italy; AOU Careggi, Firenze, Italy.  
9:45 am

GS3-02. PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

 
  Dowsett M, Jacobs S, Johnston S, Bliss J, Wheatley D, Holcombe C, Stein R, McIntosh S, Barry P, Dolling D, Snowdon C, Perry S, Batten L, Dodson A, Martins V, Modi A, Cornman C, Puhalla S, Wolmark N, Julian T, Pogue-Geile K, Robidoux A, Provencher L, Boileau JF, Shalaby I, Thirlwell M, Fisher K, Huang Bartlett C, Koehler M, Osborne K, Rimawi M.  The Institute Of Cancer Research, London, United Kingdom; The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; Pfizer Inc, New York; Royal Cornwall Hospitals NHS Foundation Trust, Treliske, United Kingdom; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Belfast Health and Social Care Trust, Belfast, United Kingdom; Baylor College of Medicine, Houston; International Drug Development Institute, Brussels, Belgium; Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Canada; CHU de Quebec-Universite Laval, Quebec, Canada; Joe Arrington Cancer Research & Treatment Center, Lubbock, TX; Allegheny Health Network Cancer Institute, Pittsburgh; UPMC Cancer Center, Pittsburgh, PA; Centre Hospitalier Université de Montréal, Montreal, Canada; McGill University Health Centre, Montreal, Canada.
 
10:00 am

GS3-03.  Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: an EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women

 
  Gray R, Early Breast Cancer Trialists' Collaborative Group.  University of Oxford, Oxford, United Kingdom.  
10:15 am

GS3-04.  A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years - Results from 1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS)

 
  Ohtani S, Iijima K, Higaki K, Sato Y, Hozumi Y, Hasegawa Y, Takei H, Tanaka M, Yagata H, Masuoka H, Tanabe M, Egawa C, Komoike Y, Saji S, Nakamura T, Yanagita Y, Ohtsu H, Mukai H, Iwase T.   Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan; National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan; University of Tsukuba Hospital /Ibaraki Prefectural Central Hospital, Kasama, Ibaraki, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Saitama Cancer Center, Ina, Saitama, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Saitama Medical Center, Kawagoe, Saitama, Japan; Sapporo Kotoni Breast Clinic, Sapporo, Hokkaido, Japan; Kansai Rosai Hospital, Amagasaki, Hyogo, Japan; Osaka International Cancer Institute, Osaka, Japan; Fukushima Medical University, Fukushima, Japan; University of Occupational and Environmental Health, Kitakyusyu, Fukuoka, Japan; Gunma Cancer Center, Ohta, Gunma, Japan; National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan;  National Cancer Center Hospital East, Kashiwa, Chiba, Japan  
10:30 am

GS3-05.  Prospective optimization of estrogen receptor degradation yields ER ligands with variable capacities for ER transcriptional suppression

 
  Metcalfe C, Zhou W, Guan J, Daemen A, Hafner M, Blake RA, Ingalla E, Young A, Oeh J, De Bruyn T, Ubhayakar S, Chen I Giltnane JM, Li J, Wang X, Sampath D, Hager JH, Friedman LS.  Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego.  
10:45 am

GS3-06.  Dynamics of breast cancer relapse reveal molecularly defined late recurring ER-positive subgroups: Results from the METABRIC study

 
  Curtis C, Rueda OM, Sammut S-J, Chen S-F, Caswell-Jin JL, Seoane JA, Callari M, Batra R, Pereira B, Bruna A, Ali HR, Provenzano E, Liu B, Parisien M, Gillett C, McKinney S, Green A, Murphy L, Purushotham A, Ellis I, Pharoah P, Rueda C, Aparicio S, Caldas C.  Stanford University School of Medicine, Stanford, CA; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Research Institute in Oncology and Hematology, Winnipeg, MB, Canada; Guy's and St Thomas' NHS Foundation Trust, King's College London, London, United Kingdom; British Columbia Cancer Research Centre, Vancouver, BC, Canada; University of Nottingham and Nottingham University Hospital NHS Trust, Nottingham, United Kingdom; University of Cambridge Strangeways Research Laboratory, Cambridge, United Kingdom; Universidad de Valladolid Facultad de Ciencias, Valladolid, Spain.  
11:00 am

GS3-07.  Clinical utility of circulating tumor cell count as a tool to choose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial

 
                           Bidard F-C, Jacot W, Dureau S, Brain E, Bachelot T, Bourgeois H, Goncalves A, Ladoire S, Naman H, Dalenc F, Gligorov J, Espie M, Levy C, Ferrero J-M, Loirat D, Cottu P, Dieras V, Simondi C, Berger F, Alix-Panabieres C, Pierga J-Y.  Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France.  
11:15 am

GS3-08.  Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the Phase III SOLAR-1 trial

 
  Juric D, Ciruelos E, Rubovsky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu Y-S, Inoue K, Takahashi M, Pápai Z, Longin A-S, Mills D, Wilke C, Hirawat S, Babbar N, Andre F.  Massachusetts General Hospital, Boston, MA; Hospital Universitario 12 de Octubre, Madrid, Spain; National Institute of Oncology, Budapest, Hungary; Institut de Cancérologie de l'Ouest, St Herblain, France; German Breast Group, Neu-Isenburg, Germany; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Aichi Cancer Center, Nagoya, Japan; Istituto Oncologico Veneto, Padua, Italy; Vanderbilt University, Nashville, TN; Chaim Sheba Medical Center, Tel Hashomer, Israel; Kanagawa Cancer Center, Yokohama, Japan; National Taiwan University Hospital, Taipei, Taiwan; Saitama Cancer Center, Saitama, Japan; NHO Hokkaido Cancer Center, Sapporo, Japan; Duna Medical Center, Budapest, Hungary; Novartis Pharma S.A.S, Paris, France; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Gustave Roussy, Université Paris-Sud, Villejuif, France.  
     
10:45 am - 5:00 pm EXHIBITS - Hall 2  
     
11:30 am - 12:00 pm

AACR  Distinguished Lectureship in Breast Cancer Research - Hall 3

 
       What Can We Learn from Breast Cancers that Metastasize or Don't?
Zena Werb, PhD
University of California San Francisco
San Francisco, CA

     
12:00 pm - 1:00 pm  BREAK  
     
12:00 pm - 1:00 pm  CAREER DEVELOPMENT FORUM - Room 304 
 
  Panel Q&A: Getting the Most from Your Training
A distinguished panel of researchers will answer questions from the audience and provide advice for a candid view into the skills, work, and resources needed for a productive and fulfilling traineeship.  Panelists represent the spectrum of basic to clinical researchers, ensuring that students, postdoctoral fellows and medical residents alike receive valuable insight on their fellowships.  Please join us for an inside look into how to get the most from your training!

Panel:
Joan S. Brugge, PhD
Ludwig Cancer Center at Harvard
Boston, MA

Jenny C. Chang, MD
Houston Methodist Cancer Center
Houston, TX

Richard L. Crownover, MD, PhD
UT Health San Antonio
San Antonio, TX

Heide L. Ford, PhD
University of Colorado School of Medicine
Aurora, CO
 
     
1:00 pm - 2:00 pm

CASE DISCUSSION 1 – Stars at Night Ballroom 1&2 - 3rd Level

 
  Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Panelists:

Reshma Jagsi, MD, DPhil
Michigan Medicine
Ann Arbor, MI

Bruce Mann, MBBS
The Royal Women's Hospital
Parkville, AUSTRALIA

Suleiman Massarweh, MD
Stanford University
Stanford, CA

Lajos Pusztai, MD, DPhil
Yale Cancer Center
New Haven, CT

Valencia Robinson
Florida Breast Cancer Foundation
Daytona, FL

Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL 
 
      

1:00 pm - 2:00 pm TRANSLATIONAL SCIENCE FORUM 1 - Stars at Night Ballroom 3&4 - 3rd Level  
 

PI3K Pathway in Breast Cancer
Moderator: Carlos L. Arteaga, MD
UT Southwestern
Simmons Comprehensive Cancer Center
Dallas, TX

The complexity of targeting PI3K for cancer therapy
Lewis C. Cantley, PhD
The Sandra and Edward Meyer Cancer Center
New York, NY

Clinical development of inhibitors of the PI3K pathway
TBD

Lessons learned from the development of PI3K inhibitors in metastatic breast cancer
Dejan Juric, MD
Massachusetts General Hospital
Boston, MA

 
     
2:15 pm - 3:15 pm MINI-SYMPOSIUM 1 - Hall 3  
 

Man vs. Machine: Now and in the Future
Moderator: Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX

Deep learning systems for reading mammograms and breast tomosynthesis
Nico Karssemeijer, PhD
Radboud University Medical Centre
Nijmegen, NETHERLANDS

Artificial intelligence to optimize the accuracy and predictiveness of breast cancer pathology
Andrew H. Beck, MD, PhD
PathAI
Cambridge, MA

 
     
3:15 pm - 5:00 pm

GENERAL SESSION 4 – Hall 3
Moderator: Richard Crownover, MD, PhD
UT Health San Antonio
San Antonio, TX

 
     
3:15 pm

GS4-01. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: 10 year follow up results of the EORTC AMAROS trial (EORTC 10981/22023)

 
  Rutgers EJ, Donker M, Poncet C, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Blanken C, Orzalesi L, Klinkenbijl JH, van der Mijle HC, Veltkamp SC, van 't Riet M, Albregts M, Marinelli A, Rijna H, Tobon Morales R, Snoj M, Bundred N, Chauvet MP, Merkus JW, Petignat P, Schinagl DA, Coens C, Peric A, Bogaerts J, van Tienhoven G.  Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, Netherlands; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; University Medical Centre, Leiden, Leiden, Netherlands; Cardiff University, Cardiff, Wales, United Kingdom; Rijnstate Hospital, Arnhem, Netherlands; Careggi University Hospital, Florence, Italy; Gelre Hospital, Apeldoorn, Netherlands; Nij Smellinghe Hospital, Drachten, Netherlands; Catharina Hospital, Eindhoven, Netherlands; Amstelland Hospital, Amstelveen, Netherlands; Reinier de Graaf Hospital, Delft, Netherlands; Diakonessenhuis, Utrecht, Netherlands; Medical Center Haaglanden, Den Haag, Netherlands; Spaarne Gasthuis, Haarlem, Netherlands; St Jansdal, Harderwijk, Netherlands; Institute of Oncology, Ljubljana, Slovenia; Manchester University Hospital, Manchester, United Kingdom; Centre Oscar Lambret, Lille, France; Haga Hospital, Den Haag, Netherlands; University Hospitals of Geneva, Geneva, Switzerland; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; Academic Medical Centre, Amsterdam, Netherlands.  
3:30 pm

GS4-02. Regional lymph node irradiation in early stage breast cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials

 
  Dodwell D, Taylor C, McGale P, Coles C, Duane F, Gray R, Kühn T, Hannequiin C, Oliveros S, Wang Y, Overgaard J, Poortmans P, Whelan T.  Nuffield Dept of Population Health, Oxford, United Kingdom; Oncology Centre - University of Cambridge, Cambridge, United Kingdom; Klinikum Esslingen, Esslingen, Germany; Saint Louis Hospital, Paris, France; Oxford University Hospitals, Oxford, United Kingdom; Aarhus University Hospital, Aarhus, Denmark; Institut Curie, Paris, France; McMaster University and Juravinski Cancer Centre, Hamilton, Canada.  
3:45 pm

GS4-03. RAPID: A randomized trial of accelerated partial breast irradiation using 3-dimensional conformal radiotherapy (3D-CRT)

 
  Whelan T, Julian J, Levine M, Berrang T, Kim D-H, Gu CS, Germain I, Nichol A, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera F, Balkwill S, Chafe S, McGowan T, Muanza T, Beckham W, Chua B, Olivotto I.  McMaster University, Hamilton, ON, Canada; University of British Columbia, Victoria, BC, Canada; Universitaire de Quebec, Quebec, QC, Canada; University of British Columbia, Vancouver, BC, Canada; University of Manitoba, Winnipeg, MB, Canada; University of Montreal, Montreal, QC, Canada; University of British Columbia, Kelowna, BC, Canada; University of Toronto, Toronto, ON, Canada; University of Calgary, Calgary, AB, Canada; University of Western Ontario, London, ON, Canada; University of British Columbia, Surrey, BC, Canada; University of Alberta, Edmonton, AB, Canada; McGill University, Montreal, QC, Canada; University of New South Wales, Sydney, Australia.  
4:00 pm

GS4-04. Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer

 
  Vicini FA, Cecchini RS, White JR, Julian TB, Arthur DW, Rabinovitch RA, Kuske RR, Parda DS, Ganz PA, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, Costantino JP, Bear HD, Germaine I, Gustafson G, Grossheim L, Peterson IA, Hudes RS, Curran, Jr. WJ, Wolmark N.  NRG Oncology, Pittsburgh, PA; MHP Radiation Oncology Institute St. Joseph's Mercy Hospital, Pontiac; NRG Oncology/NSABP, Pittsburgh; University of Pittsburgh, Pittsburgh; Ohio State University Comprehensive Cancer Center, Columbus; Allegheny Health Network Cancer Institute, Pittsburgh; Virginia Commonwealth University, Richmond; University of Colorado Cancer Center, Aurora; Arizona Breast Cancer Specialists /Arizona Oncology Services, Scottsdale; University of California at Los Angeles, Los Angeles; Carnegie Mellon University, Pittsburgh; American College of Radiology, Reston; Severance Biomedical Science Institute and Yonsei University College of Medicine, Seoul, Korea; University of Texas MD Anderson Cancer Center, Houston; Mayo Clinic Florida, Jacksonville; University of Michigan Health System, Ann Arbor; Orlando Health UF Health Cancer Center, Orlando; CHU de Québec – Université Laval, Pavillon Hôtel-Dieu de Québec, Quebec City; CCOP William Beaumont Hospital, Royal Oak; West Michigan Cancer Center (WMCC), Kalamazoo; Mayo Clinic, Rochester; Thomas Jefferson University/St. Agnes Hospital, Philadelphia; Winship Cancer Institute of Emory University, Atlanta.

 
4:15 pm  GS4-05. Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects  in the IMPORT HIGH trial (CRUK/06/003)
Coles CE, Griffin CL, Kirby AM, Haviland JS, Titley JC, Benstead K, Brunt AM, Chan C, Ciurlionis L, Din OS, Donovan EM, Eaton DJ Harnett AN, Hopwood P, Jefford ML, Jenkins PJ, Lee CE, McCormack M, Sherwin L, Syndikus I, Tsang Y, Twyman NI, Ventikaraman R, Wickers S, Wilcox MH, Bliss JM, Yarnold JR.  Oncology Centre, University of Cambridge, Cambridge, United Kingdom; The Institute of Cancer Research, London, United Kingdom; The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom; Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom; University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom; Nuffield Health Cheltenham Hospital, Cheltenham, United Kingdom; Aukland City Hospital, Aukland, New Zealand; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; The University of Surrey, Guildford, United Kingdom; RTTQA Mount Vernon Hospital, Northwood, United Kingdom; Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; University College London Hospitals NHS Foundation Trust, London, United Kingdom; Ipswich Hospital NHS Trust, Ipswich, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, Birkenhead, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; The Independent Cancer Patients' Voice, London, United Kingdom.

 
4:30 pm

GS4-06. Discussant

 
  Wendy A. Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX
 
 4:45 pm GS4-07. Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial 
Albain KS, Gray RJ, Sparano JA, Makower DF, Pritchard KI, Hayes DF, Geyer Jr. CE, Dees EC, Goetz MP, Olson, Jr. JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge, Jr. GW.
 
 
 
5:00 pm - 7:00 pm

Spotlight Session 5: Immunotherapy – Stars at Night Ballroom 1&2 - 3rd Level

Chair: Hope S. Rugo, MD
UCSF Medical Center
San Francisco, CA

Discussants:

New combinations and predictive factors
Rita Nanda, MD
The University of Chicago Medicine
Chicago, IL

Understanding the immune microenvironment
Roberto Salgado, MD
Peter MacCallum Cancer Centre
Melbourne, AUSTRALIA

 
     
5:00 pm - 7:00 pm  Spotlight Session 6: QOL, Survivorship, and Cost of Care - Stars at Night Ballroom 3&4 - 3rd Level  
  Chair: Sharon H. Giordano, MD, MPH
UT MD Anderson Cancer Center
Houston, TX

Discussants:

Interventions to improve quality of life in breast cancer survivors
Kathryn J. Ruddy, MD
Mayo Clinic
Rochester, MN

Costs of care, comorbidity and disparities in survivorship care
Jeanne Mandelblatt, MD, MPH
Georgetown University
Washington, DC
 
     
5:00 pm - 7:00 pm POSTER SESSION 3 & reception – Hall 1
                             
  Detection/Diagnosis  

Circulating Tumor Cells
Micrometastases
Axillary Staging and Sentinel Nodes
Biopsy Techniques

P3-01
P3-02
P3-03
P3-04

     
 

Tumor Cell and Molecular Biology

Epigenetics
Genomics
Tumor Heterogeneity/Molecular Subtypes
Molecular Profiles
Oncogenes/Tumor Suppressor Genes


P3-05
P3-06
P3-07
P3-08
P3-09

 
 
 

Prognostic and Predictive Factors

Predictive Biomarkers for Targeted Therapies
Biomarkers for Chemotherapy

P3-10
P3-11

     
 

Treatment

Radiotherapy
Breast Conservation
Other

P3-12
P3-13
P3-14



 
  Ongoing Trials

Surgery and Reconstruction
Axillary Nodes
Radiofrequency Ablation
Radiation Therapy
Metastatic Breast Cancer
Immunotherapy
HER2
Screening
Prevention
Barriers to Care
 

OT2-01
OT2-02
OT2-03
OT2-04
OT2-05
OT2-06
OT2-07
OT2-08
OT2-09
OT2-10
     
 7:30 pm OPEN SATELLITE EVENT presented by Medscape Education - Marriott Rivercenter

Debates, Dilemmas, and Consensus: Evolving Standards of Care in HER2-Positive Breast Cancer
For more information and to register for this event, please click on the link below:

https://www.medscape.org/symposium/her2-positive-breast-cancer-registration

 
     
7:30 pm OPEN SATELLITE EVENT presented by Clinical Care Options - Marriott Rivercenter

PARP Inhibitors in Breast Cancer: Expert Perspectives on Clinical Application and Genetic Testing
For more information and to register for this event, please click on the link below:

https://events.clinicaloptions.com/oncology/programs/program/?id=022097b6-21aa-e811-80de-005056943d50
 
 
Tuesday | Wednesday | Thursday | Friday | Saturday